Sanofi has narrowed down the field of potential buyers to drug companies from Brazil and India, plus several private equity funds, Reuters reports.

After ushering Juno through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set for a big payday.

Reports say that Nestle backed off as leader to buy Merck KGaA’s consumer businesses and that Pfizer has only two interested parties.

Let’s just say it hasn’t been a great week for Novo Nordisk.

AbbVie may not seem like the kind of company to chase down mammoth deals. But that doesn’t mean it won’t do just that.

Johnson & Johnson has plenty of money coming in from overseas, thanks to U.S. tax reform. But it won’t be spending it on Pfizer’s OTC unit.

Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.

Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.

Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.